EJCTS Click here for details of sales representative
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Jan T. Christenson
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Christenson, J. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Christenson, J. T.

Eur J Cardiothorac Surg 1999;15:394-400
© 1999 Elsevier Science NL


Preoperative lipid-control with simvastatin reduces the risk of postoperative thrombocytosis and thrombotic complications following CABG1

Jan T. Christenson

Department of Cardiovascular Surgery, Hôpital de la Tour, CH-1217 Meyrin-Geneva, Switzerland

Received 22 September 1998; received in revised form 21 December 1998; accepted 8 January 1999.

Tel.: +41-22-7800-294; fax: +41-22-7851-653; e-mail: jtchristenson@latour.ch

Objective: It has earlier been suggested that postoperative thrombocytosis frequently occur after coronary artery bypass grafting (CABG) and may be linked to lipid disturbances. A prospective randomized study was undertaken to evaluate if preoperative lipid-control, using HMG-CoA-reductase inhibitor (Zocor®), simvastatin, reduces the risk of postoperative thrombocytosis. Methods: Seventy-seven patients with symptomatic coronary artery disease and hypercholesterolemia (total cholesterol>=6.2 mmol/l), planned for CABG where randomly assigned to; undergo CABG without preoperation lipid control (group I, n=37) or undergo simvastatin-treatment (20 mg daily) to control their lipids (4 weeks) prior to CABG (group II, n=40). Results: Patient characteristics and operation data did not differ between the groups. Serum-cholesterol, cholesterol/HDL-cholesterol, LDL-cholesterol, Apolipoprotein A1 and Plasminogen were all significantly higher in group I patients compared with group II just prior to surgery. Other laboratory parameters did not differ. Results: In group II, total cholesterol and cholesterol/HDL-cholesterol quota were significantly lowered by simvaststin (-2 and -29%, respectively). Postoperative thrombocytosis (platelet counts>=400 000/µl) occurred significantly more frequently in group I 81% (30/37) compared with 3% (1/40) in group II, P<0.0001. Myocardial infarction after the 7th postoperative day was more often diagnosed in group I, 14 vs. 0% in group II. Postoperative transient renal failure occurred also more frequently in group I, 24% compared with 8% in group II. Other postoperative complications and laboratory data did not differ. Conclusions: This study once again underlines the importance of lipid control using HMG-CoA-reductase inhibitors (e.g. Zocor®) in patients with established coronary artery disease. For the first time it is shown that lipid-control with simvastatin prior to CABG reduces the risk of postoperative thrombocytosis, thus lowers the risk for thrombotic complications.

Key Words: Myocardial revascularization • Hypercholesterolemia • Thrombocytosis • Lipid lowering drugs




This article has been cited by other articles:


Home page
Cleveland Clinic Journal of MedicineHome page
L. S. FELDMAN and D. J. BROTMAN
Perioperative statins: More than lipid-lowering?
Cleveland Clinic Journal of Medicine, September 1, 2008; 75(9): 654 - 662.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
O. J. Liakopoulos, Y.-H. Choi, P. L. Haldenwang, J. Strauch, T. Wittwer, H. Dorge, C. Stamm, G. Wassmer, and T. Wahlers
Impact of preoperative statin therapy on adverse postoperative outcomes in patients undergoing cardiac surgery: a meta-analysis of over 30 000 patients
Eur. Heart J., June 2, 2008; 29(12): 1548 - 1559.
[Abstract] [Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
K. I. Paraskevas
Applications of statins in cardiothoracic surgery: more than just lipid-lowering
Eur. J. Cardiothorac. Surg., March 1, 2008; 33(3): 377 - 390.
[Abstract] [Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
V. Aboyans, L. Labrousse, P. Lacroix, J. Guilloux, S. Sekkal, A. Le Guyader, E. Cornu, and M. Laskar
Predictive factors of stroke in patients undergoing coronary bypass grafting: statins are protective.
Eur. J. Cardiothorac. Surg., August 1, 2006; 30(2): 300 - 304.
[Abstract] [Full Text] [PDF]


Home page
Asian Cardiovasc. Thorac. Ann.Home page
J. T Christenson and J. T Christenson
Preoperative Cholesterol and Thrombotic Complications After Coronary Bypass
Asian Cardiovasc Thorac Ann, December 1, 2000; 8(4): 315 - 321.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1999 European Association for Cardio-Thoracic Surgery. Published by Elsevier. All rights reserved.